Council Members in this Study Group: 24
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
David SykesPrincipal
PRMA Consulting Ltd.![]()
David Sykes is the founding Partner of PRMA Consulting, United Kingdom. He is an expert in pricing, reimbursement, and health outcomes within pharmaceutical and medical device sectors. Mr. Sykes has over 14 years of blue chip experience at J&J, Lilly,...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Exubera - approvable is no longer reimbursable
October 24, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the commercial success of companies going forward.